Literature DB >> 3009910

Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region.

M Robert-Guroff, S H Weiss, J A Giron, A M Jennings, H M Ginzburg, I B Margolis, W A Blattner, R C Gallo.   

Abstract

Antibody prevalences for human T-cell lymphotropic virus (HTLV) types I, II, and III were determined for 56 intravenous drug abusers from Queens, NY. While control serum samples lacked antibodies to all HTLV subgroups, seropositivity among drug users was 41% for HTLV-III, 18% for HTLV-II, and 9% for HTLV-I. Infection by HTLV-I and -II occurred independently of HTLV-III infection. Blacks had greater HTLV-III antibody prevalence than whites (54% vs 16%) and were more likely than whites to be seropositive for HTLV-I or -II (46% vs 11%). They exhibited a greater incidence than whites of double infection with HTLV-I or -II and HTLV-III (27% vs 0%), and 73% were seropositive for at least one of the viruses, compared with only 26% of the whites. The increased HTLV-I and -II infection seen in intravenous drug users suggests that once introduced into a population, these viruses may be transmitted by the same routes as HTLV-III. Transmission may have been restricted mainly to blacks in this study because of local drug use practices.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009910

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  60 in total

1.  Skin and Soft Tissue Infections in Injection Drug Users.

Authors:  Patricia D. Brown; John R. Ebright
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

Review 2.  HTLV-I infection in Britain.

Authors:  J Weber
Journal:  BMJ       Date:  1990-07-14

Review 3.  HTLV-I infection in human disease.

Authors:  D J Spalton; F Nicholson
Journal:  Br J Ophthalmol       Date:  1991-03       Impact factor: 4.638

Review 4.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

5.  Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay kits for detection of antibody to HTLV-I and -II.

Authors:  C Cossen; S Hagens; R Fukuchi; B Forghani; D Gallo; M Ascher
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

6.  The donation and sale of blood by intravenous drug users.

Authors:  D D Chitwood; J B Page; M Comerford; J A Inciardi; C B McCoy; E Trapido; S H Lai
Journal:  Am J Public Health       Date:  1991-05       Impact factor: 9.308

7.  Prevalence of HIV infection in 646 heroin addicts and outcome of HIV-related conditions in the 266 followed up.

Authors:  C Mandelli; D Conte; R Barbera; T Masullo; S Pistoso; G P Aimo; L Cesarini; M Fraguelli; G P Lorini; P A Bianchi
Journal:  Eur J Epidemiol       Date:  1991-01       Impact factor: 8.082

Review 8.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

9.  A serosurvey for HTLV-I among high-risk populations and normal adults in Egypt.

Authors:  N T Constantine; M Fathi Sheba; A L Corwin; R S Danahy; J D Callahan; D M Watts
Journal:  Epidemiol Infect       Date:  1991-10       Impact factor: 2.451

10.  HTLV-1 seroprevalence in AIDS patients and in HIV-1 seropositive and seronegative subjects at risk for AIDS in northern Italy.

Authors:  N Manca; A Caruso; C Bonfanti; E Savoldi; R Li Vigni; F Pirali; P L Sapelli; A Turano
Journal:  Eur J Epidemiol       Date:  1989-03       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.